This Article Full Text Full Text (PDF) All Versions of this Article: 91/5/1785    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bondy, C. A. Articles by Ho, V. B. Search for Related Content PubMed PubMed Citation Articles by Bondy, C. A. Articles by Ho, V. B. Related Collections Pediatric Endocrinology

Growth Hormone Treatment and Aortic Dimensions in Turner Syndrome

Developmental Endocrinology Branch (C.A.N., P.L.V., V.K.B.), National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892; and Department of Radiology (V.B.H.), Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814

Address all correspondence and requests for reprints to: C. A. Bondy, National Institute of Child Health and Human Development, National Institutes of Health, 10 Center Drive, CRC 1-3330, Bethesda, Maryland 20892. E-mail: bondyc{at}mail.nih.gov.

Background: In recent years many girls with Turner syndrome (TS) have been treated with supraphysiological doses of GH to increase adult height. In addition to promoting statural growth, GH may have direct effects on the cardiovascular system.

Objective: We sought to determine whether GH treatment affects aortic diameter in girls with TS because there is an increased risk for aortic dilation and dissection in this syndrome.

Methods: In a retrospective, cross-sectional study, we compared ascending and descending aortic diameters measured by magnetic resonance imaging in GH-treated (n = 53) vs. untreated (n = 48) patients with TS participating in a National Institutes of Health protocol between 2001 and 2004.

Results: The average duration of GH treatment was 4.7 with SE 0.4 yr (range 2–11 yr). The two groups were similar in age and weight, but GH-treated subjects were on average 8 cm taller (P = 0.002). The diameter of the ascending aorta was increased by 7.3% and descending aorta by 8.9% in the GH-treated group. However, after correction for age, height, weight, and presence of bicuspid aortic valve and coarctation, using a multiple regression, neither history of GH treatment nor the length of GH treatment had an effect on the aortic diameter. Weight (P = 0.02), height (P = 0.001), and presence of bicuspid aortic valve (P = 0.0001) were associated with larger ascending aortic diameter, whereas age (P = 0.008), height (P = 0.02), and history of coarctation (P = 0.006) were associated with larger descending aortic diameter.

Conclusions: GH treatment of girls with TS does not seem to affect ascending or descending aortic diameter above the increase related to the larger body size.

This article has been cited by other articles:

				L. Lopez, K. L. Arheart, S. D. Colan, N. S. Stein, G. Lopez-Mitnik, A. E. Lin, M. D. Reller, R. Ventura, and M. Silberbach Turner Syndrome Is an Independent Risk Factor for Aortic Dilation in the Young Pediatrics, June 1, 2008; 121(6): e1622 - e1627. [Abstract] [Full Text] [PDF]

				K. Bolar, A. R. Hoffman, T. Maneatis, and B. Lippe Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 344 - 351. [Abstract] [Full Text] [PDF]

				C. A. Bondy and for The Turner Syndrome Consensus Study Group Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 10 - 25. [Abstract] [Full Text] [PDF]